Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts

Journal of Rheumatology

Volumn 31, Issue 8, 2004, Pages 1598-1606

  Sarrazin, Patrice ^a   Hackett, Josette A ^a   Fortier, Isabelle ^a   Gallant, Maxime A ^a   De Brum Fernandes, Artur J ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Bone; Osteoclasts; Prostaglandins

Indexed keywords

11 DEOXYPROSTAGLANDIN E1; ACID PHOSPHATASE; ACTIN; BUTAPROST; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E3 RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SULPROSTONE; TARTARIC ACID; UNCLASSIFIED DRUG; 11-DEOXYPROSTAGLANDIN E1; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DRUG DERIVATIVE; EP4 RECEPTOR; ISOENZYME; MESSENGER RNA; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN EP3 RECEPTOR; TARTRATE-RESISTANT ACID PHOSPHATASE;

ARTICLE; BONE DISEASE; CONTROLLED STUDY; CYTOSKELETON; FEMUR; FETUS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LAMELLIPODIUM; OSTEOCLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TIBIA; CELL AGING; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; PHENOTYPE; PHYSIOLOGY; ULTRASTRUCTURE;

ACID PHOSPHATASE; ACTINS; ALPROSTADIL; CELL AGING; CYTOSKELETON; DINOPROSTONE; FETUS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOENZYMES; OSTEOCLASTS; PHENOTYPE; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER;

EID: 3442892958     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Vaananen HK, Horton M. The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. J Cell Sci 1995;108:2729-32.
2. Zambonin-Zallone A, Teti A, Carano A, Marchisio PC. The distribution of podosomes in osteoclasts cultured on bone laminae: effect of retinol. J Bone Miner Res 1988;3:517-23.
3. Lakkakorpi PT, Vaananen HK. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res 1991;6:817-26.
4. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113:377-81.
5. Canalis E. Novel treatments for osteoporosis. J Clin Invest 2000;106:177-9.
6. Teti A, Migliaccio S, Taranta A, et al. Mechanisms of osteoclast dysfunction in human osteopetrosis: abnormal osteoclastogenesis and lack of osteoclast-specific adhesion structures. J Bone Miner Res 1999;14:2107-17.
7. Roodman GD. Pagets disease and osteoclast biology. Bone 1996;19:209-12.
8. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000;12:195-9.
9. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
10. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest 1994;93:1095-101.
11. Sone K, Tashiro M, Fujinaga T, Romomasu T, Tokayama K, Kurome T. Long-term low-dose prostaglandin E1 administration. J Pediatr 1980;97:866-7.
12. Ueda K, Saito A, Nakano H. Cortical hyperostosis following long term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr 1980;97:834-6.
13. 2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997;20:521-6.
14. Leonhardt A, Timmermanns G, Roth B, Seyberth HW. Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatrics 1992;120:546-54.
15. Waters DJ, Caywood DD, Trachte GJ, Turner RT, Hodgson SF. Immobilization increases bone prostaglandin E. Effect of acetylsalicylic acid on disuse osteoporosis studied in dogs. Acta Orthop Scand 1991;62:238-43.
16. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995;313:36-46.
17. Raisz LG, Vanderhoek JY, Simmons HA, Kream BE, Nicolaou KC. Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. Prostaglandins 1979;17:905-14.
18. 2 increases the skeletal response to mechanical loading. J Bone Miner Res 1997;12:276-82.
19. Ma YF, Li XJ, Jee WSS, et al. Effects of prostaglandin e(2) and f-2-alpha on the skeleton of osteopenic ovariectomized rats. Bone 1995;17:549-54.
20. Bell NH, Hollis BW, Shary JR, et al. Diclofenac sodium inhibits bone resorption in postmenopausal women. Am J Med 1994;96:349-53.
21. Soekanto A, Ohya K, Ogura H. The effect of sodium salicylate on the osteoclast-like cell formation and bone resorption in a mouse bone marrow culture. Calcif Tissue Int 1994;54:290-5.
22. Saffar JL, Lasfargues JJ, Leroux P, Guez D. Regulation of osteoclastic resorption by prostanoids in vivo. C R Séances Soc Biol Fil 1993;187:608-19.
23. Kimmel DB, Coble T, Lane N. Long-term effect of naproxen on cancellous bone in ovariectomized rats. Bone 1992;13:167-72.
24. Huang YS, Rousseau K, Le Belle N, et al. Insulin-like growth factor-I stimulates gonadotrophin production from eel pituitary cells: a possible metabolic signal for induction of puberty. J Endocrinol 1998;159:43-52.
25. McAllister TN, Du T, Frangos JA. Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochem Biophys Res Commun 2000;270:643-8.
26. Conaway HH, Diez LF, Raisz LG. Effects of prostacyclin and prostaglandin E1 on bone resorption in the presence and absence of parathyroid hormone. Calcif Tissue Int 1986;38:130-4.
27. 2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinol 1998;139:3157-64.
28. Chambers TJ, Ali NN. Inhibition of osteoclastic motility by prostaglandins I2, E1, E2 and 6-oxo-E1. J Pathol 1983;139:383-97.
29. Sarrazin P, Bkaily G, Hache R, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids 2001;64:203-10.
30. 2 receptor subtypes in human bone tissue: Differences in foetal, adult normal, osteporotic and pagetic bone. Prostaglandins Leukot Essent Fatty Acids 2004;70:431-9.
31. Chambers TJ, McSheehy PMJ, Thomson BM, Fuller K. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 1985;116:234-9.
32. Moonga BS, Alam AS, Bevis PJ, et al. Regulation of cytosolic free calcium in isolated rat osteoclasts by calcitonin. J Endocrinol 1992;132:241-9.
33. Kuestner RE, Elrod RD, Grant FJ, et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol 1994;46:246-55.
34. Bhattacharya M, Peri K, Ribeiro-da-Silva A, et al. Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 1999;274:15719-24.
35. Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998;95:15792-7.
36. Schievella AR, Regier MK, Smith WL, Lin LL. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem 1995;270:30749-54.
37. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998;273:9886-93.
38. Kanai N. Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL. Identification and characterization of a prostaglandin transporter. Science 1995;268:866-9.
39. Gay CV, Weber JA. Regulation of differentiated osteoclasts. Crit Rev Eukaryot Gene Expr 2000;10:213-30.
40. Banan A, Smith GS, Kokoska ER, Miller TA. Role of actin cytoskeleton in prostaglandin-induced protection against ethanol in an intestinal epithelial cell line. J Surg Res 2000;88:104-13.
41. Hasegawa H, Negishi M, Katoh H, Ichikawa A. Two isoforms of prostaglandin EP3 receptor exhibiting constitutive activity and agonist-dependent activity in Rho-mediated stress fiber formation. Biochem Biophys Res Commun 1997;234:631-6.
42. 2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor. Calcif Tissue Int 2000;67:85-92.
43. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226.
44. Breyer MD, Breyer RM. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 2001;63:579-605.
45. Zalavary S, Bengtsson T. Adenosine inhibits actin dynamics in human neutrophils: evidence for the involvement of cAMP. Eur J Cell Biol 1998;75:128-39.
46. 2 initially inhibits and then stimulates bone resorption in isolated rabbit osteoclast cultures. Bone Miner 1989;7:255-66.
47. 2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 2000;15:1321-9.
48. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449-55.
49. Sakuma Y, Tanaka K, Suda M, et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun 2000;68:6819-25.
50. 2 in prostaglandin e receptor EP4-knockout mice. J Biol Chem 2000;275:19819-23.
51. Suzawa T, Miyaura C, Inada M, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinol 2000;141:1554-9.
52. Sakuma Y, Tanaka K, Suda M, et al. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 2000;15:218-27.